Clinical Trials for K-NK Therapies
K-NK002 is an investigational product of Kiadis Pharma and safety and efficacy has not been established by any jurisdiction or agency.
We are developing our products in a tightly regulated environment of clinical studies that are reviewed and approved by the national respective authorities to establish a maximum safety level for patients. Currently, therefore, access to our investigational cell therapy is limited to patients meeting the eligibility criteria of our clinical trials.
Upcoming Clinical Trial: K-NK002
A phase 2 study, NCT04395092, evaluating haplo-identical NK cells to prevent post-transplant relapse in AML and MDS. This study was designed based on promising clinical proof-of-concept data from MD Anderson Cancer Center showing a Complete Remission (CR) rate of 69% in contrast to historical CR rates of 20-26%.2 K-NK002 will be conducted in collaboration with the Bone Marrow Transplant Clinical Trial Network (BMT CTN), which consists of the premier transplant centers in the United States.3
Upcoming Clinical Trial: K-NK003
A phase 1 study will begin in 2020 evaluating NK cells as a treatment for patients with relapse and refractory acute myeloid leukemia (AML).
Kiadis has a number of programs evaluating its K-NK-cell therapies for the treatment of hematologic and solid cancers.
For all trials
If you are a medical professional and would like information about becoming an investigator for one of our clinical trials, please contact email@example.com